AMO Pharma
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Park Row, Leeds, West Yorkshire, LS1 5...Phone Number
+44 1483319070Website
www.amo-pharma.comRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About AMO Pharma
AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe childhood onset neurogenetic disorders with limited or no treatment options.Explore more
AMO Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AMO Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if AMO Pharma is spiking on competitors!
AMO Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if AMO Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when AMO Pharma launches new products
Funding: Get notified immidiatlly once AMO Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at AMO Pharma
Click to see if AMO Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on AMO Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at AMO Pharma
Find 3 more new buyers
Compare Similar Companies to AMO Pharma
Compare insights from companies similar to AMO Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AMO Pharma
$5.6M
11-50
Private
$60M
2015
BK
Bernard KiernanHead Vice President, Chemistry, Manufacturing & Controls
Company Profile Activity
Activity Insights
AMO Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AMO Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AMO Pharma.
AMO Pharma financials insights
Gather financial insights about AMO Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$25M
2020
Unspecified
$35M
AMO Pharma Tech Stack
A closer look at the technologies used by AMO Pharma
Most Recent Scoops
Funding
Executive Move
Board of Directors
Funding
Funding
Funding
AMO Pharma News & Media
AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1
-Four years of study data highlight continued favorable safety profile for AMO-02 -FDA meeting planned in Q4 2025 to discuss potential route to NDA submission for congenital myotonic dystrophy LONDON, Sept. 15, 2025 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held...AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Phase 2 proof-of-concept trial with AMO Pharma investigative therapy AMO-02 now underway at 17 sites across Canada; 120 patients expected to enroll LONDON, Sept. 8, 2025 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company...AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy
Company will conduct Phase 3 trial of AMO-02 (tideglusib) in adults to support a future submission for marketing authorization in Type 1 myotonic dystrophy in both adult and pediatric indications. LONDON, May 2, 2024 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held...AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy
LONDON, Feb. 15, 2024 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, today announced a collaboration with Population Health Research Institute...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AMO Pharma
Sign Up For FreeTo access detailed company insights
AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe childhood onset neurogenetic disorders with limited or no treatment options.... Read More
